Generalized Anxiety Disorder Clinical Trial
Official title:
Randomized Clinical Trial Comparing Mindfulness, Pharmacological Treatment, and Control Group in Generalized Anxiety Disorder (GAD)
The literature suggests that Mindfulness Based Intervention may be effective in the treatment of anxiety symptoms. The objective of this study is to compare the clinical effectiveness of a Mindfulness Based Intervention - the Mind in Body Training (MBT) - with a selective serotonin reuptake inhibitor (Fluoxetine) and an active control group (Quality of Life) through different biological and clinical outcomes, as well as evaluate some possible mechanisms of treatment response. Methods: it is a three armed randomized, controlled clinical trial. Participants with General Anxiety Disorder will be recruited. A community sample of 192 participants will be randomly allocated to the MBT, Fluoxetine or Quality of Life Group. Instruments measuring anxiety, worry and meta-worry symptoms, quality of life, acceptance and self-compassion, mindfulness, rumination and emotion regulation will be applied. The patients will be submitted to Error Related Negativity (ERN) and Heart Rate Variability (HRV) measures. The primary outcome is the effectiveness of MBT compared with Fluoxetine and Quality of Life Group in symptomatic outcomes. The secondary outcome are the effectiveness os these interventions in emotional regulation process and biological measures (ERN and HRV), and the evaluation of BMT mechanisms through possible mediation of treatment response for emotional processes like mindfulness, acceptance and self-compassion, biological changes (ERN and HRV), and metacognition.
Generalized Anxiety Disorder (GAD) is the most prevalent Anxiety Disorder after Specific
Phobia. It is characterized by persistent and excessive anxiety and worry about different
domains of life that is difficult to control, and the individuals can experience physical
symptoms, like restlessness or feeling keyed up or on edge, being easily fatigued, difficulty
concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. Also,
GAD is one of the most common mental disorders in primary care settings, and it is associated
with increased use of health care resources and disability, functional impairment,
psychiatric and medical comorbidities.
Despite its prevalence and impairment, this disorder is under-recognized, and less than
one-third of patients are adequately treated. The literature demonstrates that either
psychotropic medications or cognitive behavior therapy (CBT) appear to be effective for
treating GAD. However, a substantial number of patients do not respond to initial treatment,
and, although the response rates are inconsistent across studies, only 38% of the treated
patients have a remission after five years. Moreover, GAD is usually a chronic disorder with
a waxing and waning course, requiring a long-term treatment.
In relation to some biological mechanisms in GAD, some studies report an enhanced
Error-Related Negativity (ERN) and a lower Heart Rate Variability (HRV) in GAD patients. The
first biological marker could be associated with anxious apprehension and the main findings
are found in GAD while the second one reflects a reduction in parasympathetic modulation. On
the other hand, it is already known that mindfulness meditation practice is associated with
increase in autonomic regulation by stimulating the parasympathetic system. In relation to
cognitive factors, the literature demonstrates that GAD patients have a higher level of
experiential avoidance and distress about emotions, more negative believes about worry and
meta-worry.
Mindfulness is a practice developed to foster self-regulation. Historically, the mindfulness
exercises used in clinical protocols are linked with the Buddhist framework in which it is a
means to alleviate suffering and cultivate compassion. In the West, the role of mindfulness
in health promotion has been the target of studies since the 70s and it has been incorporated
in cognitive-behavioural treatments. The Body in mind training (BMT) is a treatment protocol
that focuses on movement and motor system as a tool for mindfulness practice. More than three
decades of studies have shown the positive effects of mindfulness based interventions (MBIs)
in both mental and physical health and quality of life either in general population or
clinical populations. Also, MBIs seem to be effective and a lasting alternative to treat
anxiety. In relation to GAD, some studies have shown that MBI's are effective, but, in
generally, they are limited by the small sample size or the use of waiting list control
instead of an active control group.
So, the objective of this research is to evaluate the effectiveness of BMT intervention and
compared to Fluoxetine and a Quality of Life Group in the treatment of GAD patients. Also, we
intend to evaluate some biological and cognitive mechanisms of these different treatments
through mediators analysis.
It is a single blind Randomized Controlled Trial with three arms of treatments. The
individuals will be recruited in the community. Generalized Anxiety patients (according to
Mini-International Neuropsychiatric Interview) will be randomly allocated (in a 1:1:1 ratio)
to receive either antidepressant: BMT: Control Group. Research assessors will be masked.
Because of the nature of the interventions, patients and clinicians will be aware of
treatment allocation. The duration of the treatments is 8 weeks.
Before, in the week 5, and after the interventions, participants will be assessed with the
Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression (CGI), Anxiety Sensitivity
Index (ASI), Penn State Worry Questionnaire (PSWQ), Difficulties in Emotion Regulation Scale
(DERS), Five Facet Mindfulness Questionnaire (FFMQ), Self-Compassion Scale (SCS), Action and
Acceptance Questionnaire (AAQ), Ruminative Response Scale (RRS), Metacognition Questionnaire
(MCQ-30), Meta-worry Questionnaire (MWQ), WHOQOL-Bref. Also, before the interventions,
participants will answer the Early Life Experiences Scale (ELES) and Early Memories of Warmth
and Safeness Scale (EMWSS). The HRV and ERN will be assessed before and after the
interventions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |